Morgan Stanley Maintains Equal-Weight on Ionis Pharmaceuticals, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Equal-Weight rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $45 to $48.
November 03, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Ionis Pharmaceuticals and raises the price target from $45 to $48. This could potentially lead to a positive sentiment among investors.
The raised price target by Morgan Stanley indicates a positive outlook for Ionis Pharmaceuticals. This could potentially lead to increased investor confidence and a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100